AR058615A1 - Mutantes de fsh - Google Patents
Mutantes de fshInfo
- Publication number
- AR058615A1 AR058615A1 ARP060105722A ARP060105722A AR058615A1 AR 058615 A1 AR058615 A1 AR 058615A1 AR P060105722 A ARP060105722 A AR P060105722A AR P060105722 A ARP060105722 A AR P060105722A AR 058615 A1 AR058615 A1 AR 058615A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- fsh
- mutant
- mutants
- pharmaceutical composition
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 208000021267 infertility disease Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen mutantes de FSH con mayor glicosilacion y mayores vidas medias. También se describe el uso de mutantes de FSH para inducir foliculogenesis en pacientes humanos. Reivindicacion 1: Un ácido nucleico que codifica una subunidad-alfa mutante de FSH en donde la subunidad-alfa comprende una secuencia seleccionada entre el grupo formado por SEC ID N°: 4-5. Reivindicacion 2: Un vector que comprende el ácido nucleico de acuerdo con la reivindicacion 1. Reivindicacion 5: Una célula huésped que comprende el vector de acuerdo con la reivindicacion 2. Reivindicacion 11: Un método para producir un mutante de FHS que comprende: proveer una célula que comprende el ácido nucleico de acuerdo con la reivindicacion 1, y un segundo ácido nucleico que codifica SEC ID N°: 3; cultivar la célula bajo condiciones que permiten la expresion de los ácidos nucleicos primero y segundo. Reivindicacion 15: Una composicion farmacéutica que comprende el mutante FSH de acuerdo con la reivindicacion 1 y opcionalmente un portador o excipiente farmacéuticamente aceptable. Reivindicacion 16: Un método para tratar un mamífero infértil, que comprende administrar a un mamífero que lo necesita la composicion farmacéutica de acuerdo con la reivindicacion 15.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75363705P | 2005-12-22 | 2005-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058615A1 true AR058615A1 (es) | 2008-02-13 |
Family
ID=38875495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105722A AR058615A1 (es) | 2005-12-22 | 2006-12-21 | Mutantes de fsh |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7740862B2 (es) |
| EP (1) | EP1976872B1 (es) |
| JP (1) | JP5249044B2 (es) |
| KR (1) | KR20080087854A (es) |
| CN (1) | CN101341169B (es) |
| AR (1) | AR058615A1 (es) |
| AU (1) | AU2006346358B2 (es) |
| BR (1) | BRPI0620223A2 (es) |
| CA (1) | CA2630857A1 (es) |
| EA (1) | EA013975B1 (es) |
| EC (1) | ECSP088646A (es) |
| ES (1) | ES2543198T3 (es) |
| IL (1) | IL192096A (es) |
| MX (1) | MX2008008322A (es) |
| MY (1) | MY145839A (es) |
| NZ (1) | NZ568475A (es) |
| UA (1) | UA93893C2 (es) |
| WO (1) | WO2008010840A2 (es) |
| ZA (1) | ZA200804677B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103509121B (zh) | 2012-11-22 | 2015-01-28 | 苏州康宁杰瑞生物科技有限公司 | 一种fsh融合蛋白及其制备方法和用途 |
| KR101947340B1 (ko) * | 2017-05-05 | 2019-02-12 | 주식회사 유비프로틴 | FSHα 반감기를 증가시키는 방법 |
| KR101947341B1 (ko) * | 2017-05-05 | 2019-02-12 | 주식회사 유비프로틴 | FSHβ 반감기를 증가시키는 방법 |
| CN114213523B (zh) * | 2021-11-15 | 2024-07-09 | 广州源博医药科技有限公司 | 一种用于重组蛋白的高糖基化修饰序列及其重组猪促卵泡激素和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2082424C (en) * | 1990-05-08 | 2003-09-23 | Robert K. Campbell | Analogs of glycoprotein hormones having altered immunological characteristics, efficacy and/or receptor specificity |
| GB9403600D0 (en) * | 1994-02-24 | 1994-04-13 | Univ Glasgow | Three dimensional hormone structure |
| WO2001058493A1 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | Conjugates of follicle stimulating hormones |
| AU2002368265B2 (en) * | 2001-10-22 | 2007-06-07 | Merck Serono Sa | Mutant glycoproteins |
| UA88879C2 (en) | 2003-09-02 | 2009-12-10 | Эплайд Рисерч Системз Эрс Холдинг Н.В. | Fsh glycosylation mutant |
| RU2006136919A (ru) * | 2004-03-19 | 2008-04-27 | Трофоджен, Инк. (Us) | Суперагонисты фолликулостимулирующего гормона |
| ZA200805194B (en) * | 2006-01-17 | 2009-10-28 | Serono Lab | Novel FSH glycosylation variant D3N |
-
2006
- 2006-12-21 ES ES06851498.3T patent/ES2543198T3/es active Active
- 2006-12-21 EA EA200870108A patent/EA013975B1/ru not_active IP Right Cessation
- 2006-12-21 AR ARP060105722A patent/AR058615A1/es not_active Application Discontinuation
- 2006-12-21 CA CA002630857A patent/CA2630857A1/en not_active Abandoned
- 2006-12-21 BR BRPI0620223-3A patent/BRPI0620223A2/pt not_active IP Right Cessation
- 2006-12-21 KR KR1020087018024A patent/KR20080087854A/ko not_active Application Discontinuation
- 2006-12-21 UA UAA200808445A patent/UA93893C2/ru unknown
- 2006-12-21 NZ NZ568475A patent/NZ568475A/en not_active IP Right Cessation
- 2006-12-21 JP JP2008547571A patent/JP5249044B2/ja not_active Expired - Fee Related
- 2006-12-21 CN CN2006800481289A patent/CN101341169B/zh not_active Expired - Fee Related
- 2006-12-21 AU AU2006346358A patent/AU2006346358B2/en not_active Ceased
- 2006-12-21 US US12/096,125 patent/US7740862B2/en not_active Expired - Fee Related
- 2006-12-21 EP EP06851498.3A patent/EP1976872B1/en active Active
- 2006-12-21 MX MX2008008322A patent/MX2008008322A/es active IP Right Grant
- 2006-12-21 WO PCT/US2006/048898 patent/WO2008010840A2/en active Application Filing
- 2006-12-21 ZA ZA200804677A patent/ZA200804677B/xx unknown
- 2006-12-21 MY MYPI20082262A patent/MY145839A/en unknown
-
2008
- 2008-06-12 IL IL192096A patent/IL192096A/en not_active IP Right Cessation
- 2008-07-22 EC EC2008008646A patent/ECSP088646A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101341169B (zh) | 2012-09-05 |
| AU2006346358B2 (en) | 2012-01-19 |
| BRPI0620223A2 (pt) | 2011-11-01 |
| WO2008010840A2 (en) | 2008-01-24 |
| JP5249044B2 (ja) | 2013-07-31 |
| US7740862B2 (en) | 2010-06-22 |
| ECSP088646A (es) | 2008-08-29 |
| EA200870108A1 (ru) | 2009-12-30 |
| ES2543198T3 (es) | 2015-08-17 |
| IL192096A0 (en) | 2008-12-29 |
| JP2009521222A (ja) | 2009-06-04 |
| UA93893C2 (en) | 2011-03-25 |
| EP1976872A2 (en) | 2008-10-08 |
| CA2630857A1 (en) | 2008-01-24 |
| NZ568475A (en) | 2010-10-29 |
| AU2006346358A1 (en) | 2008-01-24 |
| CN101341169A (zh) | 2009-01-07 |
| MY145839A (en) | 2012-04-30 |
| ZA200804677B (en) | 2009-10-28 |
| WO2008010840A3 (en) | 2008-03-20 |
| IL192096A (en) | 2012-02-29 |
| AU2006346358A2 (en) | 2008-07-31 |
| KR20080087854A (ko) | 2008-10-01 |
| MX2008008322A (es) | 2008-10-01 |
| US20090018070A1 (en) | 2009-01-15 |
| EP1976872B1 (en) | 2015-06-17 |
| EA013975B1 (ru) | 2010-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4163291A1 (en) | Polypeptide vaccine coupled with tlr7 agonist for novel coronavirus and use thereof | |
| ES2636653T3 (es) | Mutantes degradantes del proteoglucano para el tratamiento del SNC | |
| CN107148427B (zh) | 新型免疫原性肽 | |
| DE69518642T2 (de) | Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c | |
| CO5690564A2 (es) | Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero | |
| ES2623141T3 (es) | Nuevos métodos para modular respuestas inflamatorias y/o inmunitarias | |
| US20100247560A1 (en) | Mutant botulinum neurotoxin serotype a polypeptide and uses thereof | |
| TW425286B (en) | Conjugates useful in the treatment of prostate cancer | |
| AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
| AR076147A1 (es) | Fusiones y conjugados de farmaco. composicion farmaceutica. uso. procedimiento. | |
| CO5570710A2 (es) | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico | |
| CN109069605A (zh) | 新免疫原性CD1d结合肽 | |
| KR960704041A (ko) | 사람 인터루킨-10의 효능제 및 길항제(Agonists and antagonists of human interleukin-10) | |
| AR058615A1 (es) | Mutantes de fsh | |
| WO2011163628A2 (en) | Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof | |
| JP2004534503A5 (es) | ||
| EP1944038A1 (en) | Dengue virus capsid protein which induces a protective response and pharmaceutical composition | |
| BR9815551A (pt) | Vacina de envoltório dimérica recombinante contra infecção flaviviral | |
| ATE103297T1 (de) | Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea. | |
| PT1093465E (pt) | ''processo para produzir ou intensificar uma resposta de células t contra uma célula alvo, utilizando um complexo compreendendo uma molécula hla de classe i e meios de ligação'' | |
| CN110325206A (zh) | 用于管理病毒感染的多肽 | |
| AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
| TW201925240A (zh) | 肽共軛物、共軛過程及其用途 | |
| CN109293782A (zh) | 融合多肽及使用方法 | |
| Green et al. | Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 (7-36) amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |